Pharmaceutical Analytical Testing Outsourcing Market Report 2026

The pharmaceutical analytical testing outsourcing market size has grown strongly in recent years. It will grow from $9.43 billion in 2025 to $10.28 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to rising drug development complexity, high in house lab costs, growth in contract research organizations, stricter regulatory testing needs, expansion of generic drug pipelines.

The pharmaceutical analytical testing outsourcing market size is expected to see strong growth in the next few years. It will grow to $14.6 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to growth in biologics and cell therapies, increasing regulatory scrutiny, expansion of virtual pharma models, rising small biotech outsourcing, demand for faster batch release. Major trends in the forecast period include specialized third party analytical labs, integrated method validation services, high throughput bioanalytical testing, regulatory ready testing packages, end to end quality control outsourcing.

The rising complexity of drug molecules is expected to propel the growth of the pharmaceutical analytical testing outsourcing market. Drug molecule complexity refers to the growing structural, chemical, and functional sophistication of modern therapeutics, including biologics, peptides, oligonucleotides, and targeted therapies that require highly accurate characterization and validation. This increasing complexity is driven by advances in specialty and precision medicine, which require advanced analytical techniques to ensure product quality, safety, and regulatory compliance. As internal analytical capabilities often struggle to meet the technical and regulatory requirements associated with complex molecules, pharmaceutical companies are increasingly turning to specialized third-party analytical testing providers. Outsourcing offers access to advanced instrumentation, specialized expertise, and scalable capacity that are often impractical or too expensive to maintain in-house. For instance, according to MedChem Australia, an Australia-based national drug discovery initiative, approximately 55 new drugs were approved in 2023, including 17 biologics and 9 peptide- or oligonucleotide-based therapies (TIDES). These therapeutic modalities require sophisticated analytical approaches such as mass spectrometry, bioassays, and advanced stability testing, thereby increasing reliance on outsourced analytical testing services. Therefore, the increasing complexity of drug molecules is contributing to the growth of the pharmaceutical analytical testing outsourcing market.

Key companies operating in the pharmaceutical analytical testing outsourcing market are focusing on advancing automated and digital analytical testing platforms to improve the accuracy, efficiency, and regulatory compliance of quality control (QC) testing across the drug development and manufacturing lifecycle. These advancements aim to enhance method robustness, increase throughput, and ensure reliable impurity profiling, identity confirmation, and batch release testing in accordance with regulatory requirements. For example, in March 2023, Eurofins Discovery, a US-based contract research organization (CRO), expanded its analytical testing services by introducing automated, label-free mass spectrometry-based analytical platforms to support regulated pharmaceutical quality control applications. These platforms enable high-throughput, reproducible analysis of drug substances and drug products without reliance on fluorescent or radioactive labels, preserving sample integrity and improving data reliability. The enhanced capabilities support critical QC activities such as impurity detection, identity testing, and method validation, enabling pharmaceutical manufacturers to meet stringent regulatory standards while accelerating testing timelines.

In December 2024, Novo Holdings A/S, a Denmark-based private holding and investment company, acquired Catalent, Inc., for an undisclosed amount. Through this acquisition, Novo Holdings aims to enhance its life sciences investment portfolio by supporting Catalent’s growth as a leading global contract development and manufacturing organization, strengthening capabilities across pharmaceutical development, manufacturing, analytical testing, and full life-cycle supply for pharmaceutical and biotechnology companies. Catalent, Inc., is a US-based contract development and manufacturing organization (CDMO) that offers outsourced services to pharmaceutical, biotechnology, and consumer health companies across the entire product lifecycle.

Major companies operating in the pharmaceutical analytical testing outsourcing market are Thermo Fisher Scientific Inc., IQVIA Holdings Inc., Laboratory Corporation of America Holdings, ICON plc, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Intertek Group plc, Charles River Laboratories International Inc., West Pharmaceutical Services Inc., Element Materials Technology Group Limited, Recipharm AB, Almac Group Limited, Pace Analytical Services LLC, Cotecna Inspection S.A., BioAgilytix Labs LLC, BA Sciences Inc., Toxikon Corporation, Frontage Laboratories Inc., Syngene International Limited.

Tariffs on laboratory instruments, analytical equipment, and specialty reagents are increasing service delivery costs in pharmaceutical analytical testing outsourcing. Advanced testing segments using imported instruments are most affected. Labs in regions dependent on imported chromatography and spectroscopy systems face higher capital expenses. This can raise outsourcing service fees. At the same time, tariffs are encouraging domestic lab equipment manufacturing and regional testing hubs.

The pharmaceutical analytical testing outsourcing market research report is one of a series of new reports that provides pharmaceutical analytical testing outsourcing market statistics, including pharmaceutical analytical testing outsourcing industry global market size, regional shares, competitors with a pharmaceutical analytical testing outsourcing market share, detailed pharmaceutical analytical testing outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical analytical testing outsourcing industry. This pharmaceutical analytical testing outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmaceutical analytical testing outsourcing refers to the practice of engaging third-party laboratories or service providers to conduct analytical testing of pharmaceutical products. It allows pharmaceutical companies to access specialized expertise, advanced equipment, and scalable testing capacity without significant in-house investment. It ensures precise, reliable, and regulatory-compliant testing of drugs while reducing costs and operational workload for manufacturers.

The primary service types of pharmaceutical analytical testing outsourcing include method development and validation, stability testing, microbial testing, raw material testing, and other service types. Method development and validation refer to the creation and optimization of analytical methods to ensure accuracy, consistency, and adherence to regulatory requirements. These services are applied to product categories including small molecules and generics, biologics and biosimilars, cell and gene therapies, vaccines, and medical devices. They are used across application stages such as clinical, preclinical, and other applications, and are utilized by end users including pharmaceutical companies, biotechnology companies, contract research organizations (CROs), and other end users.

The pharmaceutical analytical testing outsourcing market includes revenues earned by entities through the analytical method development, analytical method validation, bioanalytical testing services, impurity profiling, contract research services, quality control testing, formulation analysis, bioequivalence studies, and regulatory support services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.